Stroke, Vol 23, 865-869, Copyright © 1992 by American Heart Association
K Yoshida, GF Burton, JS McKinney, H Young and EF Ellis
BACKGROUND AND PURPOSE: The purpose of this study was to determine the
distribution of polyethylene glycol-conjugated superoxide dismutase in the
brain, cerebrospinal fluid, and various organs. METHODS: Distribution of
iodine-125-labeled polyethylene glycol-conjugated superoxide dismutase was
determined in three groups of male Sprague- Dawley rats: a normotensive
sham control group (n = 9) and groups given 125I-labeled polyethylene
glycol-conjugated superoxide dismutase either 30 minutes before (n = 10) or
30 minutes after (n = 7) norepinephrine- induced hypertensive injury.
RESULTS: In the first 30 minutes after intravenous administration,
polyethylene glycol-conjugated superoxide dismutase plasma activity
declined to 70% of the initial value and then decreased negligibly between
30 and 90 minutes. Levels of 125I-labeled polyethylene glycol-conjugated
superoxide dismutase in normotensive animals were low in the brain and
cerebrospinal fluid and highest in kidney. Brain levels of polyethylene
glycol-conjugated superoxide dismutase were elevated only in those rats
that received it before hypertensive injury; however, cerebrospinal fluid
levels were elevated in animals receiving the drug either before or after
hypertensive injury. CONCLUSION: Our results suggest that the blood-brain
barrier becomes more permeable to polyethylene glycol-conjugated superoxide
dismutase only during the hypertensive period but that the blood-
cerebrospinal fluid barrier sustains more permanent injury. We suggest that
the therapeutic effectiveness of polyethylene glycol-conjugated superoxide
dismutase in hypertensive brain injury is due to its action in the vascular
wall or to its extracellular activity in the cerebrospinal fluid.
ARTICLES
Brain and tissue distribution of polyethylene glycol-conjugated superoxide dismutase in rats
Department of Pharmacology, Medical College of Virginia, Virginia Commonwealth University, Richmond.
This article has been cited by other articles:
![]() |
C.-s. Liang, A. Yatani, Y. Himura, M. Kashiki, and S. Y. Stevens Desipramine attenuates loss of cardiac sympathetic neurotransmitters produced by congestive heart failure and NE infusion Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1729 - H1736. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1992 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |